Eralp, Yesim2023-02-212023-02-212022-01-0110.3390/vaccines10081262https://hdl.handle.net/11443/1082http://dx.doi.org/10.3390/vaccines10081262mRNA-based therapeutics pose as promising treatment strategies for cancer immunotherapy. Improvements in materials and technology of delivery systems have helped to overcome major obstacles in generating a sufficient immune response required to fight a specific type of cancer. Several in vivo models and early clinical studies have suggested that various mRNA treatment platforms can induce cancer-specific cytolytic activity, leading to numerous clinical trials to determine the optimal method of combinations and sequencing with already established agents in cancer treatment. Nevertheless, further research is required to optimize RNA stabilization, delivery platforms, and improve clinical efficacy by interacting with the tumor microenvironment to induce a long-term antitumor response. This review provides a comprehensive summary of the available evidence on the recent advances and efforts to overcome existing challenges of mRNA-based treatment strategies, and how these efforts play key roles in offering perceptive insights into future considerations for clinical application.mRNA vaccinesmRNA delivery platformscancer therapeuticscancer immunotherapycancer specific immune responseclinical applications in cancer therapyArticleWOS:000845140400001